{"url_path":"/sec/sldb/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-219337-index.html","accession_number":"0001193125-26-219337","cik":"0001707502","ticker":"SLDB","issuer_name":"Solid Biosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-219337-index.html","primary_entity_key":"0001707502","primary_entity_name":"Solid Biosciences Inc."},"word_count":196,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.\n\nRecent Sales of Unregistered Securities\n\nExcept as set forth below, we did not sell any securities during the three months ended March 31, 2026 that were not registered under the Securities Act of 1933, as amended (the \"Securities Act\"), and that have not otherwise been described in a Current Report on Form 8-K.\n\nFollowing the dosing of the first participant in the Phase 1b FALCON clinical trial of SGT-212, a $7.5 million development milestone became payable to FA212 LLC. On January 15, 2026, we made the milestone payment in the form of 1,316,899 shares of our common stock, see Note 2 - FA212 Asset Acquisition. The shares were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act as a privately negotiated transaction not involving any public offer or solicitation. On March 19, 2026, we filed a registration statement covering the resale of the shares of common stock issued to FA212 LLC, which was declared effective on March 31, 2026. None of the shares were sold through an underwriter and accordingly, there were no underwriting discounts or commissions involved."}